Treatment choices for the “severe acute respiratory syndrome‐related coronavirus‐2 (SARS‐
CoV‐2)” are inadequate, having no clarity on efficacy and safety profiles. Currently, no …

The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials
of whole-lung low-dose radiation therapy (LDRT; 0.3–1.5 Gy) that are now progressing to …

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a
pandemic disease and is the major cause of deaths worldwide. The clinical complexities …

Abstract Introduction Following the Covid-19 pandemic spread, changes in clinical practice
were necessary to limit the pandemic diffusion. Also, oncological practice has undergone …

Study of the human microbiota has been a centuries-long endeavor, but since the inception
of the National Institutes of Health (NIH) Human Microbiome Project in 2007, research has …

The fear of radiation has been present almost since the discovery of radiation, but has
intensified since the “dawn of the atomic age” over 75 y ago. This fear has often served as …

The Coronavirus disease 2019 (COVID-19) pandemic continues to spread worldwide with
over 260 million people infected and more than 5 million deaths, numbers that are …

Infection, the invasion of pathogenic microorganisms and viruses, causes reactive
inflammation mediated by endogenous signals, with influx of leucocytes with distinct …

Simple Summary There are limited available data indicating that in oxygen-dependent
elderly patients with COVID-19-associated pneumonia, low-dose whole-lung radiation …

Purpose Current treatments for coronavirus disease 2019 (COVID-19) lung disease have
limited efficacy. Low-dose radiation therapy (LDRT) has received both interest and criticism …